$469 Million is the total value of BVF INC/IL's 34 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 57.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FWP | Sell | FORWARD PHARMA A/Ssponsored adr | $25,885,000 | +5.6% | 1,424,611 | -1.2% | 5.52% | -9.0% |
| ARQL | Sell | ARQULE INC | $14,155,000 | +12.1% | 7,450,128 | -5.6% | 3.02% | -3.5% |
| VTAE | Sell | VITAE PHARMACEUTICALS INC | $8,212,000 | -40.7% | 761,079 | -63.6% | 1.75% | -48.9% |
| ESPR | Sell | ESPERION THERAPEUTICS INC NE | $4,932,000 | -51.9% | 499,142 | -17.7% | 1.05% | -58.6% |
| QLTI | Sell | QLT INC | $3,203,000 | -71.8% | 2,255,476 | -60.4% | 0.68% | -75.7% |
| CALA | Sell | CALITHERA BIOSCIENCES INC | $450,000 | -51.4% | 121,400 | -25.5% | 0.10% | -58.1% |
| NRXGQ | Exit | NEPHROGENEX INC | $0 | – | -392,156 | -100.0% | -0.05% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -50,000 | -100.0% | -0.08% | – |
| BOTA | Exit | BIOTA PHARMACEUTIALS INC | $0 | – | -350,776 | -100.0% | -0.13% | – |
| Exit | ARRAY BIOPHARMA INCnote 3.000% 6/0 | $0 | – | -2,500,000 | -100.0% | -0.50% | – | |
| LOXO | Exit | LOXO ONCOLOGY INC | $0 | – | -74,870 | -100.0% | -0.51% | – |
| CPXX | Exit | CELATOR PHARMACEUTICALS INC | $0 | – | -800,000 | -100.0% | -2.18% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -1,755,745 | -100.0% | -4.75% | – |
| ONTY | Exit | ONCOTHYREON INC | $0 | – | -18,799,368 | -100.0% | -5.91% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 37 | Q4 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 32 | Q1 2024 | 2.8% |
| XOMA CORP DEL | 31 | Q2 2024 | 7.3% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| CYTOMX THERAPEUTICS INC | 29 | Q2 2024 | 5.3% |
| KURA ONCOLOGY INC | 28 | Q2 2024 | 5.1% |
| CORVUS PHARMACEUTICALS INC | 28 | Q1 2024 | 2.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| GLYCOMIMETICS INC | 27 | Q2 2024 | 5.7% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 4 | 2024-08-22 |
| 13F-HR | 2024-08-14 |
| 3 | 2024-08-01 |
| 4 | 2024-06-28 |
| 4 | 2024-06-18 |
| 4 | 2024-06-10 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.